As previously reported (31, 33), treatment with LRRK2-IN-1 resulted in a substantial reduction in both total DCLK1 and phospho-DCLK1 expression levels in all HNSCC cell lines analyzed (Figure 1B). The gene discussed is DCLK1; the disease is head and neck squamous cell carcinoma.